Advanced

Coffee and tea consumption, genotype- based CYP1A2 and NAT2 activity and colorectal cancer risk- Results from the EPIC cohort study

Dik, Vincent K.; Bueno-de-Mesquita, H. B(as); Van Oijen, Martijn G. H.; Siersema, Peter D.; Uiterwaal, Cuno S. P. M.; Van Gils, Carla H.; Van Duijnhoven, Fraenzel J. B.; Cauchi, Stephane; Yengo, Loic and Froguel, Philippe, et al. (2014) In International Journal of Cancer 135(2). p.401-412
Abstract
Coffee and tea contain numerous antimutagenic and antioxidant components and high levels of caffeine that may protect against colorectal cancer (CRC). We investigated the association between coffee and tea consumption and CRC risk and studied potential effect modification by CYP1A2 and NAT2 genotypes, enzymes involved in the metabolization of caffeine. Data from 477,071 participants (70.2% female) of the European Investigation into Cancer and Nutrition (EPIC) cohort study were analyzed. At baseline (1992-2000) habitual (total, caffeinated and decaffeinated) coffee and tea consumption was assessed with dietary questionnaires. Cox proportional hazards models were used to estimate adjusted hazard ratio's (HR) and 95% confidence intervals (95%... (More)
Coffee and tea contain numerous antimutagenic and antioxidant components and high levels of caffeine that may protect against colorectal cancer (CRC). We investigated the association between coffee and tea consumption and CRC risk and studied potential effect modification by CYP1A2 and NAT2 genotypes, enzymes involved in the metabolization of caffeine. Data from 477,071 participants (70.2% female) of the European Investigation into Cancer and Nutrition (EPIC) cohort study were analyzed. At baseline (1992-2000) habitual (total, caffeinated and decaffeinated) coffee and tea consumption was assessed with dietary questionnaires. Cox proportional hazards models were used to estimate adjusted hazard ratio's (HR) and 95% confidence intervals (95% CI). Potential effect modification by genotype-based CYP1A2 and NAT2 activity was studied in a nested case-control set of 1,252 cases and 2,175 controls. After a median follow-up of 11.6 years, 4,234 participants developed CRC (mean age 64.78.3 years). Total coffee consumption (high vs. non/low) was not associated with CRC risk (HR 1.06, 95% CI 0.95-1.18) or subsite cancers, and no significant associations were found for caffeinated (HR 1.10, 95% CI 0.97-1.26) and decaffeinated coffee (HR 0.96, 95% CI 0.84-1.11) and tea (HR 0.97, 95% CI 0.86-1.09). High coffee and tea consuming subjects with slow CYP1A2 or NAT2 activity had a similar CRC risk compared to non/low coffee and tea consuming subjects with a fast CYP1A2 or NAT2 activity, which suggests that caffeine metabolism does not affect the link between coffee and tea consumption and CRC risk. This study shows that coffee and tea consumption is not likely to be associated with overall CRC. What's new? Coffee and tea contain numerous compounds that may protect against colorectal cancer (CRC). In this study of more than 475,000 participants over more than a decade, the authors investigated whether coffee or tea consumption is associated with an altered risk of developing CRC. They also asked whether genetic variations in two enzymes involved in caffeine metabolism (CYP1A2 and NAT2) might affect this risk. They conclude that neither consumption patterns, nor genetic differences in caffeine metabolism, appear to have a significant impact on CRC risk. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Colorectal cancer, coffee, tea, CYP1A2, NAT2
in
International Journal of Cancer
volume
135
issue
2
pages
401 - 412
publisher
John Wiley & Sons
external identifiers
  • wos:000335460400018
  • scopus:84900036010
ISSN
0020-7136
DOI
10.1002/ijc.28655
language
English
LU publication?
yes
id
73011e4a-ec91-4c36-9c08-249e50996c89 (old id 4558658)
date added to LUP
2014-08-01 07:40:24
date last changed
2017-10-01 03:13:34
@article{73011e4a-ec91-4c36-9c08-249e50996c89,
  abstract     = {Coffee and tea contain numerous antimutagenic and antioxidant components and high levels of caffeine that may protect against colorectal cancer (CRC). We investigated the association between coffee and tea consumption and CRC risk and studied potential effect modification by CYP1A2 and NAT2 genotypes, enzymes involved in the metabolization of caffeine. Data from 477,071 participants (70.2% female) of the European Investigation into Cancer and Nutrition (EPIC) cohort study were analyzed. At baseline (1992-2000) habitual (total, caffeinated and decaffeinated) coffee and tea consumption was assessed with dietary questionnaires. Cox proportional hazards models were used to estimate adjusted hazard ratio's (HR) and 95% confidence intervals (95% CI). Potential effect modification by genotype-based CYP1A2 and NAT2 activity was studied in a nested case-control set of 1,252 cases and 2,175 controls. After a median follow-up of 11.6 years, 4,234 participants developed CRC (mean age 64.78.3 years). Total coffee consumption (high vs. non/low) was not associated with CRC risk (HR 1.06, 95% CI 0.95-1.18) or subsite cancers, and no significant associations were found for caffeinated (HR 1.10, 95% CI 0.97-1.26) and decaffeinated coffee (HR 0.96, 95% CI 0.84-1.11) and tea (HR 0.97, 95% CI 0.86-1.09). High coffee and tea consuming subjects with slow CYP1A2 or NAT2 activity had a similar CRC risk compared to non/low coffee and tea consuming subjects with a fast CYP1A2 or NAT2 activity, which suggests that caffeine metabolism does not affect the link between coffee and tea consumption and CRC risk. This study shows that coffee and tea consumption is not likely to be associated with overall CRC. What's new? Coffee and tea contain numerous compounds that may protect against colorectal cancer (CRC). In this study of more than 475,000 participants over more than a decade, the authors investigated whether coffee or tea consumption is associated with an altered risk of developing CRC. They also asked whether genetic variations in two enzymes involved in caffeine metabolism (CYP1A2 and NAT2) might affect this risk. They conclude that neither consumption patterns, nor genetic differences in caffeine metabolism, appear to have a significant impact on CRC risk.},
  author       = {Dik, Vincent K. and Bueno-de-Mesquita, H. B(as) and Van Oijen, Martijn G. H. and Siersema, Peter D. and Uiterwaal, Cuno S. P. M. and Van Gils, Carla H. and Van Duijnhoven, Fraenzel J. B. and Cauchi, Stephane and Yengo, Loic and Froguel, Philippe and Overvad, Kim and Bech, Bodil H. and Tjonneland, Anne and Olsen, Anja and Boutron-Ruault, Marie-Christine and Racine, Antoine and Fagherazzi, Guy and Kuehn, Tilman and Campa, Daniele and Boeing, Heiner and Aleksandrova, Krasimira and Trichopoulou, Antonia and Peppa, Eleni and Oikonomou, Eleni and Palli, Domenico and Grioni, Sara and Vineis, Paolo and Tumino, Rosaria and Panico, Salvatore and Peeters, Petra H. M. and Weiderpass, Elisabete and Engeset, Dagrun and Braaten, Tonje and Dorronsoro, Miren and Chirlaque, Maria-Dolores and Sanchez, Maria-Jose and Barricarte, Aurelio and Zamora-Ros, Raul and Argueelles, Marcial and Jirström, Karin and Wallström, Peter and Nilsson, Lena M. and Ljuslinder, Ingrid and Travis, Ruth C. and Khaw, Kay-Tee and Wareham, Nick and Freisling, Heinz and Licaj, Idlir and Jenab, Mazda and Gunter, Marc J. and Murphy, Neil and Romaguera-Bosch, Dora and Riboli, Elio},
  issn         = {0020-7136},
  keyword      = {Colorectal cancer,coffee,tea,CYP1A2,NAT2},
  language     = {eng},
  number       = {2},
  pages        = {401--412},
  publisher    = {John Wiley & Sons},
  series       = {International Journal of Cancer},
  title        = {Coffee and tea consumption, genotype- based CYP1A2 and NAT2 activity and colorectal cancer risk- Results from the EPIC cohort study},
  url          = {http://dx.doi.org/10.1002/ijc.28655},
  volume       = {135},
  year         = {2014},
}